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Abstract
Introduction The gene XRCC1  (X-ray repair cross-
complementing group 1) encodes a protein involved in DNA
base excision repair. Two non-synonymous polymorphisms in
XRCC1 (Arg194Trp and Arg399Gln) have been shown to alter
DNA repair capacity in some studies in vitro. However, results
of previous association studies of these two XRCC1 variants
and breast cancer have been inconsistent. We examined the
association between polymorphisms in XRCC1  and breast
cancer in the American Cancer Society Cancer Prevention
Study II (CPS-II) Nutrition Cohort, a large prospective study of
cancer incidence in the USA.
Methods Among the 21,965 women who were cancer-free in
1992 and gave blood between 1998 and 2001, 502
postmenopausal breast cancer cases were diagnosed between
1992 and 2001; 502 controls were matched to cases on age,
race/ethnicity, and date of blood collection. Genotyping on DNA
extracted from buffy coat was performed with Taqman.
Conditional logistic regression was used to examine the
association between each polymorphism and breast cancer risk
controlling for breast cancer risk factors. We also examined
whether factors associated with DNA damage, such as smoking
and antioxidant intake, modified the association between
XRCC1 polymorphisms and breast cancer.
Results We observed a significant inverse association between
Trp194 carriers (Trp/Trp and Trp/Arg) compared with Trp194
non-carriers in relation to breast cancer (Arg/Arg) (odds ratio
(OR) 0.62, 95% confidence interval (CI) 0.40 to 0.95). The
inverse association between breast cancer and Trp194 carriers
compared with non-carriers was slightly stronger among
smokers (OR 0.47, 95% CI 0.24 to 0.94) than never smokers
(OR 0.78, 95% CI 0.43 to 1.40). An increased risk associated
with the Arg399Gln polymorphism (Gln/Gln versus Arg/Arg)
was observed only among women who reported ever smoking
cigarettes (OR 2.76, 95% CI 1.36 to 5.63), and not in women
who were lifelong non-smokers (OR 0.64, 95% CI 0.33 to
1.26). No other factor examined modified the association
between XRCC1 polymorphisms and breast cancer risk.
Conclusion Our results support the hypothesis that genetic
variation in XRCC1, particularly in Arg194Trp, may influence
postmenopausal breast cancer risk. In our study, genetic
variation in XRCC1  Arg399Gln was associated with breast
cancer risk only among women with a history of smoking
cigarettes.
Introduction
Base excision repair (BER) corrects localized DNA damage
such as oxidized or fragmented lesions and non-bulky adducts
[1]. Sources of oxidative damage include ionizing radiation and
chemical carcinogens in tobacco smoke [1,2]. In the absence
of this repair process, oxidized lesions and non-bulky adducts
may block DNA replication or cause cytotoxic mutations and
genetic instability [3]. The gene XRCC1 (X-ray repair cross-
complementing group 1) encodes a protein involved in DNA
BER that is essential in drawing different components of BER
to the site of DNA damage and promoting efficiency of the
BER pathway [4,5].
BER = base excision repair; CI = confidence interval; CPS-II = Cancer Prevention Study II; OR = odds ratio; XRCC1 = X-ray cross-complementing 
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The XRCC1 gene contains 17 exons and is located on chro-
mosome 19q13.2 [6]. Although many polymorphisms have
been documented [7], two non-synonymous polymorphisms in
XRCC1  (Arg194Trp (C→T allelic change) and Arg399Gln
(G→A allelic change)) have been shown to alter DNA repair
capacity in some phenotypic studies and have received con-
siderable attention. The Trp194 variant has been associated
with increased BER capacity, whereas the Gln399 variant has
been associated with reduced repair capacity [8-11].
Because of its important role in the repair capacity of BER, var-
iability in XRCC1 expression has been examined extensively in
relation to various age-related diseases, including cancer [12].
DNA repair proficiency has also been proposed as a potential
susceptibility factor for breast cancer [13].
So far, 12 observational studies have examined XRCC1 poly-
morphisms Arg194Trp and Arg399Gln in relation to breast
cancer risk, with inconsistent results [7,14-24]. Some of these
studies suggest that associations between XRCC1 polymor-
phisms and breast cancer risk are stronger in women who
smoke or who have higher exposure to various antioxidants
[7,14,24,25]. However, 8 of the 12 studies included fewer
than 250 cases and had limited power to examine relation-
ships in potentially important subgroups, such as smokers
[14-17,19,21-23]. Among the remaining studies with larger
sample sizes [18,20,24,25], two studies did not examine
potential interactions with factors such as smoking [18,20],
one reported effect modification by antioxidants, but not smok-
ing [7,25], and the last reported a stronger association with
Arg399Gln in non-smokers with detectable DNA-adduct lev-
els [24]. Previous studies that examined the relationship
between other XRCC1 polymorphisms and breast cancer risk
generally have been null [12].
To our knowledge, only one previous study observed an asso-
ciation with any XRCC1  polymorphisms aside from
Arg194Trp and Arg399Gln [19]: they observed an associa-
tion with the Arg280His polymorphism in their relatively small
(n = 250 cases) study population. Although the Arg280His
polymorphism is non-synonymous, there is no functional data
to support its potential role in repair capacity. A larger study (n
= 1,000 cases) conducted by Han et al. [25] was unable to
replicate the earlier finding, and they did not observe any asso-
ciation with other polymorphisms other than those at codons
194 and 399. Furthermore, they identified that most XRCC1
polymorphisms are all part of one haplotype block, but did not
observe an association with haplotype blocks [7]. On the con-
trary, they observed an association with only Arg194Trp and
Arg399Gln polymorphisms and breast cancer risk. Thus, in
the present analysis, we examined the association between
the two non-synonymous polymorphisms in XRCC1 that have
been shown to have functional relevance in DNA repair capac-
ity (Arg194Trp (rs1799782) and Arg399Gln (rs25487)) and
postmenopausal breast cancer risk in a case-control study
nested in the American Cancer Society Cancer Prevention
Study II (CPS-II) Nutrition Cohort.
Materials and methods
Study population
Women in this analysis were drawn from the 97,786 female
participants in the CPS-II Nutrition Cohort, which was estab-
lished by the American Cancer Society in 1992 as a subgroup
of the larger 1982 CPS-II baseline mortality cohort [26]. Most
participants were aged 50 to 74 years at enrollment in 1992.
At baseline they completed a 10-page self-administered ques-
tionnaire that included questions on demographic, reproduc-
tive, medical, behavioral, environmental, and dietary factors.
Beginning in 1997, follow-up questionnaires were sent to
cohort members every 2 years to update exposure information
and to ascertain newly diagnosed cancers. Incident cancers
reported on the questionnaires were verified through medical
records, linkage with state cancer registries, or death
certificates.
From June 1998 to June 2001, blood samples were collected
from a subgroup of 39,376 cohort members (n  = 21,965
women). After obtaining informed consent, we collected a
maximum of 43 ml of non-fasting whole blood from each par-
ticipant and samples were separated into aliquots of serum,
plasma, red blood cells, and buffy coat. Samples then were
frozen in liquid nitrogen vapor phase at about -130°C for long-
term storage.
Among the 21,965 women with blood samples who were can-
cer-free and postmenopausal in 1992, 502 postmenopausal
breast cancer cases diagnosed between 1992 and 2001
were reported through follow-up questionnaires and subse-
quently verified. For all cases, questionnaire information on risk
factors for breast cancer was collected before the diagnosis
of cancer (that is, in 1992); however, collection of DNA from
buffy coat occurred in 1998 to 2001, in some cases after or
only slightly before cancer diagnosis. For each case, we ran-
domly selected one cancer-free (except non-melanoma skin
cancer) female Nutrition Cohort control matched on single
year of age (±6 months), race/ethnicity (white, African Ameri-
can, Hispanic, Asian, other/unknown), date of blood collection
(within 6 months), and selected from individuals who were
cancer-free (except for non-melanoma skin cancer) at the
beginning of the interval preceding the diagnosis of each case
using risk-set sampling [27]. The women who provided blood
specimens were similar to the overall population in the distri-
bution of most demographic and lifestyle characteristics.
Laboratory
DNA was extracted from buffy coat and genotyping assays
were performed with TaqMan (Applied Biosystems, Foster
City, CA) as described previously [25]. Genotyping was per-
formed by laboratory personnel blinded to case-control status,
and 10% blind duplicates were randomly interspersed withAvailable online http://breast-cancer-research.com/content/7/6/R1168
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the case-control samples to validate genotyping procedures.
Concordance for the quality control samples was 100%.
Overall success rate for the genotyping assays was at least
95%.
Statistical analysis
We used a χ2 test to assess whether XRCC1 genotype distri-
butions were in Hardy-Weinberg equilibrium. Conditional
logistic regression was used to examine the association
between the XRCC1 polymorphisms and breast cancer in two
models, one controlling for matching factors only and the other
controlling for matching factors and other possible
confounders.
Conditional logistic regression modeling was performed
because controls were individually matched at the time of
selection to each case patient. Potential confounders included
in the multivariate models included education (up to and
including high school graduate, some college, college gradu-
ate or higher), age at menopause (less than 45, 45 to 54, 55
or more years, unknown) and menarche (less than 12/missing,
12 or more years), parity (nulliparous, 1 to 2, 3 or more,
unknown), age at first live birth (less than 25, 25 or more,
unknown), personal history of benign breast disease (yes, no),
family history of breast cancer in mother or sisters (yes, no),
alcohol intake (none, not more than one drink per day, more
than one drink per day, unknown), postmenopausal hormone
replacement use (never, current estrogen replacement ther-
apy, current combination estrogen–progestin replacement
therapy, former estrogen replacement therapy, former estro-
gen–progestin replacement therapy, unknown), smoking sta-
tus (never, ever, unknown), body mass index (less than 25, 25
to less than 30, 30 or more, unknown), and physical activity
(metabolic equivalents (MET-hours) per week) (less than 7, 7
to less than 17.5, 17.5 to less than 31.5, 31.5 or more,
unknown). With the exception of age at menopause (8.5%
missing), all covariates had less than 3.5% values unknown.
To test whether factors proposed to be associated with oxida-
tive stress modified the association between XRCC1 polymor-
phisms and breast cancer risk, we constructed multiplicative
interaction terms with cigarette smoking, fruit and vegetable
intake, alcohol intake, physical activity, body mass index, folate
intake, and multivitamin use. We also tested for potential inter-
action between the two polymorphisms of interest. Statistical
interaction was assessed in multivariate models using the like-
lihood ratio test, and p < 0.05 was considered statistically sig-
nificant [28].
Results
Genotyping data were missing on 6 cases and 9 controls for
Arg194Trp and on 27 cases and 23 controls for Arg399Gln.
All genotypes were in Hardy–Weinberg equilibrium. Cases
and controls were largely white (99%), with a median age of
62 years (range 43 to 75) at enrollment in 1992. Table 1
shows the genotype frequencies, odds ratios (ORs) and 95%
confidence intervals (CIs) for the association between XRCC1
polymorphisms and breast cancer. Because the Trp194 allele
is uncommon (the allele frequency among controls was 7.4%),
logistic regression models combined the Trp194 carriers (Trp/
Trp and Arg/Trp genotypes combined) and compared them
with non-carriers (Arg/Arg). After adjustment for various fac-
tors, breast cancer risk was 38% lower among Trp194 carri-
ers than among non-carriers (OR 0.62, 95% CI 0.40 to 0.95).
Risk was 27% higher among women who were homozygous
for the Gln399 variant than among women homozygous for the
wild-type (Arg) allele, although this was not statistically signif-
icant (OR 1.27, 95% CI 0.79 to 2.02; Table 1).
Table 1
Conditional logistic regression models examining the association between XRCC1 polymorphisms and postmenopausal breast 
cancer risk
Polymorphism No. of cases No. of controls OR (95% CI)a OR (95% CI)b
Arg194Trp (485 pairs)
Arg/Arg 437 415 1.00 (reference) 1.00 (reference)
Arg/Trp or Trp/Trpc 48 70 0.66 (0.45–0.97) 0.62 (0.40–0.95)
Arg399Gln (452 pairs)
Arg/Arg 196 194 1.00 (reference) 1.00 (reference)
Arg/Gln 195 202 0.95 (0.71–1.27) 1.01 (0.73–1.39)
Gln/Gln 61 56 1.08 (0.71–1.63) 1.27 (0.79–2.02)
Arg/Gln or Gln/Gln 256 258 0.98 (0.75–1.28) 1.06 (0.78–1.44)
aOdds ratio and corresponding 95% confidence interval adjusted for matched pairs; bmultivariate odds ratio and corresponding 95% confidence 
interval adjusted for: matched pairs, body mass index, age at menopause, age at menarche, alcohol intake, education, parity, age at first live birth, 
physical activity, history of breast cysts, family history of breast cancer in mother or sister, use of hormone replacement therapy, and smoking 
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We hypothesized a priori that the association between
XRCC1  polymorphisms and breast cancer risk might be
stronger in women who had experienced greater exposure to
DNA-damaging agents, such as tobacco smoke. Carriers of
Trp194 were at lower risk of breast cancer than Trp194 non-
carriers regardless of smoking status, although the inverse
association was slightly attenuated among lifelong non-smok-
ers (ever smokers OR 0.47, 95% CI 0.24 to 0.94; never smok-
ers OR 0.78, 95% CI 0.43 to 1.40; interaction p = 0.28; Table
2). For the Arg399Gln polymorphism, results differed by
smoking status (interaction p = 0.01). Among women who had
ever smoked cigarettes, the OR was 2.76 when comparing
the Gln/Gln399 genotype with the Arg/Arg399 genotype
(95% CI 1.36 to 5.63), whereas no increased risk was asso-
ciated with this polymorphism among lifelong non-smokers
(OR 0.64, 95% CI 0.33 to 1.26; Table 2).
The association between XRCC1 polymorphisms and breast
cancer risk did not differ by other environmental factors exam-
ined (data not shown). The association between XRCC1 pol-
ymorphisms and breast cancer risk also did not differ by age
at diagnosis or stage of disease (data not shown). Finally,
when assessing the combined effects of both XRCC1 poly-
morphisms on breast cancer risk, women with 'low-risk' geno-
types for both polymorphisms (Trp194 carriers and Gln399
non-carriers) had a 49% lower incidence of breast cancer than
women with 'high-risk' genotypes for both polymorphisms
(Trp194 non-carriers and Gln399 carriers; 95% CI 0.28 to
0.90).
Discussion
Results from this study support the hypothesis that genetic
variation in XRCC1 may affect a woman's breast cancer risk,
especially in women who have ever smoked cigarettes. Over-
all, women carrying the Trp194 allele had a 38% lower
incidence of breast cancer than women who were Trp194
non-carriers. This association persisted regardless of smoking
history. In contrast, the relationship between the Arg399Gln
polymorphism and breast cancer risk seemed to be limited to
women who had ever smoked. Among ever smokers, women
with the Gln/Gln399 genotype had a 2.76-fold higher risk of
breast cancer than women with the Arg/Arg399 genotype;
Table 2
Conditional logistic regression models examining XRCC1 polymorphisms and postmenopausal breast cancer stratified by smoking 
status.
Polymorphism Never smokers Ever smokers
Arg194Trp
Arg/Arg
No. of cases/no. of controls 217/237 216/175
ORa (95% CI) 1.00 (ref.) 1.00 (ref.)
Arg/Trp or Trp/Trp
No. of cases/no. of controls 26/36 21/32
ORa (95% CI) 0.78 (0.43–1.40) 0.47 (0.24–0.94)
Interaction p = 0.28
Arg399Gln
Arg/Arg
No. of cases/no. of controls 107/104 88/88
ORa (95% CI) 1.00 (ref.) 1.00 (ref.)
Arg/Gln
No. of cases/no. of controls 100/112 92/89
ORa (95% CI) 0.91 (0.57–1.43) 1.06 (0.66–1.72)
Gln/Gln
No. of cases/no. of controls 23/35 38/20
ORa (95% CI) 0.64 (0.33–1.26) 2.76 (1.36–5.63)
Interaction p = 0.01
aMultivariate odds ratio and corresponding 95% confidence interval adjusted for: matched pairs, body mass index, age at menopause, age at 
menarche, alcohol intake, education, parity, age at first live birth, physical activity, history of breast cysts, family history of breast cancer in mother 
or sister, use of hormone replacement therapy, and smoking status. XRCC1, X-ray cross-complementing group 1.Available online http://breast-cancer-research.com/content/7/6/R1168
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however, we did not observe an increased risk among women
who had never smoked.
Our findings are consistent with those from four previous stud-
ies of XRCC1  polymorphisms and breast cancer risk that
reported an inverse association between the Trp194 carriers
and breast cancer risk in mostly Caucasian [7,14] and other
[15,22] ethnic populations. Other previous studies observed a
borderline positive [16,17,23] or no [19,24] association
between the Trp194 carriers and breast cancer risk. The
Arg399Gln polymorphism has been associated with breast
cancer risk in only two studies [15,23], whereas most studies
observed no overall association [7,14,16-22,24].
XRCC1  Arg194Trp and Arg399Gln polymorphisms have
been shown to affect XRCC1 protein-product expression and
to alter BER capacity [8-11]. Oxidative stress caused by ciga-
rette smoking can induce oxidative DNA damage; minor varia-
tions in DNA repair capacity may therefore more significantly
influence risk in subpopulations that experience greater DNA
damage, such as smokers. Polymorphisms in XRCC1 have
been associated with risk of many smoking-related cancers
such as lung, bladder, and esophageal cancer [12]. However,
few studies have examined the relationship between XRCC1
polymorphisms and breast cancer risk in subgroups of the
population that may experience higher levels of DNA damage,
such as smokers. Only two [14,24] of four [7,14,20,24] previ-
ous studies that examined XRCC1  variation by smoking
reported evidence of effect modification by smoking status.
Duell  et al. [14] reported a stronger association for Gln/
Gln399 genotype with increasing duration of smoking,
whereas Shen et al. [24] observed a stronger association
among women who had never smoked but had detectable lev-
els of DNA adducts. They also reported stronger associations
for Gln/Gln399 than for Arg/Arg399 in subjects with a high
intake of antioxidants or fruit/vegetables [24]. Other studies
reported weaker inverse associations with the Trp194 allele or
stronger positive associations with Gln/Gln399 genotype and
breast cancer risk among women who drank alcohol [15], had
a positive family history of breast cancer [17], or had high
plasma folate levels [7]. However, studies that examined the
relationship between XRCC1 polymorphisms and breast can-
cer did not observe any meaningful differences by factors such
as family history [24], alcohol intake [20,24], reproductive fac-
tors [18,23], ionizing radiation [14,20], and body mass index
[18,20,24].
The primary limitation of our study is the limited statistical
power to examine whether factors such as the duration of
smoking modify the association between breast cancer and
the polymorphisms of interest. The statistical power is limited
by both small sample size and low frequency of smokers in our
cohort. Although the association observed between XRCC1
polymorphisms and breast cancer risk among smokers in this
study is interesting and adds support to the hypothesis, we
cannot exclude chance as a possible explanation for the find-
ings. For this reason, further replication of the findings is
needed in larger study populations with higher smoking prev-
alence. Strengths of our study include the prospective collec-
tion of questionnaire data, which eliminates the potential for
selection bias, and the extensive information collected from
questionnaires on various factors that may be associated with
oxidative DNA damage.
Conclusion
Our results suggest that non-synonymous coding polymor-
phisms in XRCC1 may be associated with postmenopausal
breast cancer risk, especially among women who have ever
smoked. Additional studies are needed to examine the associ-
ation of these polymorphisms with breast cancer risk, focusing
on subpopulations that may experience greater exposure to
DNA-damaging agents.
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